Calcium Channel Blocker Versus Renin–Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score‐Matched Cohort Study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70429 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Minji Jung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Stanford University Medical Center, Stanford, California, USA. Hauptthemen laut MEDLINE: Hypertension, Kidney Neoplasms, Propensity Score, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Background
Use of antihypertensive medications could be associated with an increased risk of kidney cancer. Despite their various mechanisms of action, whether this association differs between different classes of medications remains unclear.
Objective
The objective of this study is to compare the risk of kidney cancer between first‐line treatment options of antihypertensive medications in a hypertensive population.
Method
In this retrospective cohort study, we used the MarketScan Databases (2007–2021). We included individuals older than 30 years of age with a diagnosis of hypertension who received first‐line medications for hypertension, which included three classes: angiotensin‐converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and dihydropyridine calcium channel blockers (dCCB). We applied a propensity score matching method and created three separate cohorts: (1) ARB versus ACEI, (2) dCCB versus ACEI, and (3) dCCB versus ACEI. For non‐dCCB, we repeated the analyses. The primary outcome was kidney cancer incidence. To assess kidney cancer risk, we applied multivariable conditional Cox proportional hazards models.
Results
In the first cohort, ARB use was associated with an increased risk of kidney cancer compared to ACEI use (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.02–1.18). In the second cohort, dCCB use was associated with an increased risk of kidney cancer compared to ACEI use (HR 1.29, 95% CI 1.18–1.40). In the third cohort, dCCB use was associated with a higher risk of kidney cancer compared to ARB use (HR 1.17, 95% CI 1.08–1.28). Null association was shown when comparing non‐dCCB with ACEI or ARB use.
Conclusion
Use of dCCB showed a higher risk of kidney cancer compared to ACEI or ARB use in patients with hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Stanford University Medical Center, Stanford, California, USA.
- Department of Dermatology, Stanford University Medical Center, Stanford, California, USA.
- Department of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, California, USA.
ORCID-Profile: Minji Jung, Zhengyi Deng, Mingyi Li
Förderung
- NCATS NIH HHS
Zitieren
APA
Jung, M., Li, S., Deng, Z., Li, J., Li, M., Basran, S., Langston, M. E., & Chung, B. I. (2024). Calcium Channel Blocker Versus Renin–Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score‐Matched Cohort Study. Cancer Medicine. https://doi.org/10.1002/cam4.70429
Vancouver
Jung M, Li S, Deng Z, Li J, Li M, Basran S, et al. Calcium Channel Blocker Versus Renin–Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score‐Matched Cohort Study. Cancer Medicine. 2024. doi:10.1002/cam4.70429
BibTeX
@article{Jung2024,
author = {Jung, Minji and Li, Shufeng and Deng, Zhengyi and Li, Jinhui and Li, Mingyi and Basran, Satvir and Langston, Marvin E and Chung, Benjamin I},
title = {Calcium Channel Blocker Versus Renin–Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score‐Matched Cohort Study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70429}
}
EUVIMED